Visceral adipose tissue is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-07-02. Where a claim depends on a specific study, the study is described rather than over-claimed.
Development work on the compound, originally designated TH9507, focused on conditions in which reduced growth hormone signaling is thought to contribute to altered body composition. The United States Food and Drug Administration approved it in 2010 for the treatment of excess visceral abdominal fat in adults with human immunodeficiency virus infection and lipodystrophy. Later research examined other populations, including adults with mild cognitive impairment, where a large trial did not meet its primary endpoints. This mixed record illustrates how a single mechanism can produce clear effects in one setting and inconclusive results in another.
Several related peptides act on the same receptor, including sermorelin, a shorter GHRH fragment, and modified analogs such as CJC-1295 and modified GRF(1-29) that are common in research settings rather than approved products. Tesamorelin differs from growth hormone itself in that it acts upstream, prompting the pituitary to release the hormone through physiological signaling rather than supplying it directly. Terminology in the literature distinguishes GHRH analogs, growth hormone secretagogues, and recombinant growth hormone, although popular discussion often blurs these categories together. Precise naming matters when comparing study results.
Clinical investigation has focused on HIV-associated lipodystrophy, a condition in which antiretroviral therapy contributes to abnormal fat distribution. Excess visceral adipose tissue accumulates in the abdomen while peripheral fat may be lost. Tesamorelin was evaluated for reducing this visceral fat depot, with trials measuring changes in abdominal fat by imaging rather than by body weight alone. The rationale rests on the known lipolytic effects of growth hormone. Effects on visceral fat are documented, while long-term outcomes regarding cardiovascular risk remain less clearly established.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, composed of 44 amino acids. It was designed to retain the biological activity of the native hormone while resisting rapid enzymatic degradation. The compound is classified as a growth hormone secretagogue and belongs to the broader family of hypothalamic releasing factors. In research and clinical settings, it is studied for its ability to stimulate pituitary growth hormone release. Its structure includes a modification at the N-terminus that contributes to an extended half-life relative to native growth hormone-releasing hormone.
Tesamorelin binds to growth hormone-releasing hormone receptors on the surface of pituitary somatotroph cells. This binding activates adenylate cyclase, raising intracellular cyclic AMP levels and triggering the release of growth hormone into circulation. The elevated growth hormone then stimulates hepatic production of insulin-like growth factor 1. Because the effect is mediated through the endogenous axis, secretion remains subject to feedback regulation. This distinguishes it from direct growth hormone administration, which bypasses pituitary control entirely.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic 44-residue GHRH analog | Sequence matches human GHRH(1-44); differs only at the N-terminus |
| Nominal molecular mass | Approximately 5,136 Da (free base) | Small variation arises from counterion and salt form |
| Appearance | White to off-white lyophilized powder | Supplied in single-use vials intended for reconstitution |
| Solubility class | Freely soluble in water | Practically insoluble in nonpolar organic solvents |
| Typical storage | 2 to 8 degrees Celsius, protected from light | Reconstituted material is handled according to label instructions |
After injection, the peptide binds receptors on somatotroph cells in the anterior pituitary. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone into the bloodstream. Because the compound works through the body's own regulatory system, growth hormone pulses retain much of their normal feedback control. Repeated administration also raises insulin-like growth factor 1, a hormone produced mainly in the liver. Investigators treat that rise as a marker that the pituitary axis has been engaged.
Clinical study of tesamorelin has centered on adults with HIV-associated lipodystrophy, a condition in which abdominal fat accumulates while peripheral fat is lost. In controlled trials, treated participants showed reductions in visceral adipose tissue measured by imaging, alongside modest shifts in some lipid values. Effects on subcutaneous fat were smaller and less consistent across studies. Whether these changes translate into fewer cardiovascular events remains an open question, because the trials were not designed or powered to answer it.
Tesamorelin is a synthetic peptide of forty-four amino acids whose sequence reproduces human growth hormone-releasing hormone. Its distinguishing feature sits at the amino terminus, where a trans-3-hexenoyl group replaces the free amine. That acylation slows cleavage by dipeptidyl peptidase IV, an enzyme that otherwise removes the first two residues and inactivates the natural hormone quickly. The modified peptide therefore persists longer in circulation while keeping the same receptor target. It is handled as a lyophilized solid and dissolved shortly before use.
Signaling begins at the GHRH receptor, a class B G protein-coupled receptor displayed on somatotroph cells of the anterior pituitary. Receptor occupancy activates Gs proteins, which raise adenylyl cyclase activity and intracellular cyclic AMP, in turn driving protein kinase A dependent pathways. The downstream output is synthesis and pulsatile secretion of growth hormone into the bloodstream. Hepatic tissue and peripheral sites respond by increasing insulin-like growth factor 1 production. Somatostatin and IGF-1 itself supply negative feedback that caps the size and duration of each secretory burst.
Diplomatic relations between Cuba and the United States continued for some time after Batista's fall, but President Eisenhower deliberately left the capital to avoid meeting Castro during the latter's trip to Washington, D.C. in April, leaving Vice President Richard Nixon to conduct the meeting in his place. Cuba began negotiating for arms purchases from the Eastern Bloc in March 1960. The same month, Eisenhower gave approval to CIA plans and funding to overthrow Castro. In January 1961, just prior to leaving office, Eisenhower formally severed relations with the Cuban government. That April, the administration of newly elected American President John F. Kennedy mounted the unsuccessful CIA-organized ship-borne invasion of the island by Cuban exiles at Playa Girón and Playa Larga in Santa Clara Province—a failure that publicly humiliated the United States. Castro responded by publicly embracing Marxism–Leninism, and the Soviet Union pledged to provide further support. In December, the US government began a violent campaign of terrorist attacks against civilians in Cuba, and covert operations and sabotage against the administration, in an attempt to overthrow the Cuban government.
Programs are required to be accredited by SAMHSA or the Drug Enforcement Administration which is a lengthy, time- and resource-consuming process including intensive training and site visit reviews. To stay in operation, they must submit to re-accreditation every 1–3 years. Accredited programs are also able to administer buprenorphine, provided that those prescribing and administering the drug have completed the 8–24 hours of SAMHSA training. Office-based physicians who wish to prescribe buprenorphine for the treatment of opioid use disorder must also complete the required training, as well as apply for and receive a waiver from SAMHSA. Under regulation, physicians may not have more than 30 buprenorphine patients in their first year of prescribing the drug. They may apply to have this limit increased to 100 patients by year two and 275 patients by year three. In December 2015, the US Government Accountability Office began a survey of the laws and regulations around opioid treatment programs and medication-assisted treatment and found that they were barriers to getting people with opioid use disorders the treatment they need. Despite the fact that there is a shortage of opioid treatment programs across the United States, many clinicians do not want to start their own because the time and effort required to comply with the regulations is prohibitive. Individual-level barriers to accessing medication-assisted treatment also exist.
==== "Smart" hydrogel dressings ==== "Smart" hydrogels which are stimuli-responsive (i.e. thermoresponsive, bioresponsive, pH-responsive, photoresponsive, and redox-responsive) are also being produced.
A foreign-body giant cell is a collection of fused macrophages (giant cell) which are generated in response to the presence of a large foreign body. This is particularly evident with catheters, parasites, or biomaterials that are inserted into the body for replacement or regeneration of diseased or damaged tissues. Foreign body giant cells are also produced to digest foreign material that is too large for phagocytosis. The inflammatory process that creates these cells often leads to a foreign body granuloma. The human body goes through several steps when exposed to foreign biomaterial including acute and chronic inflammation, and formation of new tissue and a fibrous capsule along the surface of the implantation. Foreign body reactions, which are a type of chronic inflammation, are characterized by the presence of macrophages, monocytes, and foreign-body giant cells (FBGCs). The response of the foreign body reaction determines how compatible the implanted material will be in the body, and the members of the foreign body reaction, including the FBGC's, remain along the surface of the biomaterial for its lifetime in the body. Foreign body giant cells are formed through signaling from IL-4 and IL-13, and may fuse to produce a multinucleated cell with up to 200 nuclei within its cytoplasm.
== Structure == The notochord is a long, rod-like midline structure that develops dorsal to the gut tube and ventral to the neural tube. The notochord is composed primarily of a glycoproteins core that is encased in a sheath of collagen fibers. This is wound into two opposing helices. The glycoproteins are stored in vacuolated, turgid cells, which are covered with caveolae on their cell surface. The angle between these fibers determines whether increased pressure in the core will result in shortening and thickening versus lengthening and thinning. Alternating contraction of muscle fibers attached to each side of the notochord result in a side-to-side motion resembling stern sculling, which allows locomotion. The stiffened notochord prevents movement through telescoping motion such as that of an earthworm.
Sources: en.wikipedia.org
Delta-beta thalassemia is autosomal recessive disorder, which means both parents are affected and two copies of the gene must be present. A carrier gets a normal gene to produce hemoglobin A, from one parent and the other parent supplies a gene which makes no hemoglobin A. Delta-beta thalassemia is considered rare. Delta-beta-thalassemia is caused by deletions of the entire delta and beta genes sequences and only gamma-globin and HbF are formed. Rarely, non-deletional forms have been reported. When two delta0 mutations are inherited, no hemoglobin A2 (alpha2, delta2) are formed. This is innocuous because only 2-3% of normal adult hemoglobin is hemoglobin A2. The individual will have normal hematological parameters (erythrocyte count, total hemoglobin, mean corpuscular volume). The delta-beta thalassemia demonstrates one mutation is at the +69 position.
=== TCA cycle === When metabolites from the TCA cycle or glutamate are used as a precursor for glyceroneogenesis, the regulator in the TCA cycle can also cause fluctuations in the levels of products formed by glyceroneogenesis. Regulation of the TCA cycle is mainly determined by product inhibition and substrate availability. The TCA cycle will slow down when the environment contains excess product, or deficiency of the substrate such as ADP and NAD+.
As of 2019, there were an estimated 72,000 centenarians living in the U.S.; the 2020 census officially counted 80,139, and the 2010 census had 53,364. However, the U.S. Census Bureau claimed in 1999 that as many as a third of people stating their age as over 100 might be exaggerating. In the United States, centenarians may request a letter of congratulation from the president of the United States to mark their longevity. Strom Thurmond became the first sitting Senator to reach 100 on 5 December 2002. Jimmy Carter became the first former president to reach the age of 100 on 1 October 2024. Today also presents a segment honoring centenarians and older, sponsored by Smuckers. The tradition was created in 1983 by weather presenter Willard Scott, and is now presented by his successor Al Roker. In the state of New Mexico, centenarians have been exempt from state income tax since tax year 2002, if they are not dependents of another taxpayer.
== Treatment == Medical treatment has not proven consistently effective. Medical regimens have included tamoxifen, progesterone, bromocriptine, the gonadotropin-releasing hormone agonist leuprorelin, and testosterone. Gestational macromastia has been treated with breast reduction drugs alone without surgery. Surgical therapy includes reduction mammaplasty and mastectomy. However, breast reduction is not clinically indicated unless at least 1.8 kilograms (4.0 lb) of tissue per breast needs to be removed. In the majority of cases of macromastia, surgery is medically unnecessary, depending on body height. Topical treatment includes regimens of ice to cool the breasts. Treatment of hyperprolactinemia-associated macromastia with D2 receptor agonists such as bromocriptine and cabergoline has been found to be effective in some, but not all cases. Danazol, an antiestrogen and weak androgen, has also been found to be effective in the treatment of macromastia. When hypertrophy occurs in adolescence, noninvasive treatments, including pharmaceutical treatment, hormone therapy, and steroid use are not usually recommended due to known and unknown side effects. Once breast growth rate has stabilized, breast reduction may be an appropriate choice. In some instances after aggressive or surgical treatment, the breast may continue to grow or re-grow, a complete mastectomy may be recommended as a last resort. Pregnancy is recognized as the second most common reason for hypertrophy. When secondary to pregnancy, it may resolve itself without treatment after the pregnancy ends.
Sources: en.wikipedia.org
==== Astrocytes and blood oxygen levels ==== The Sur lab has discovered novel and critical roles for astrocytes in brain function. By high resolution imaging in the intact visual cortex, they showed that astrocytes have tuned calcium responses to visual stimuli that are mediated importantly via glutamate transporters on astrocyte processes that surround synapses, and they influence local blood flow and hence the hemodynamic signals that underlie brain imaging methods such as fMRI. Role of astrocytes in information processing and plasticity Astrocytes are also activated by neuromodulators such as acetylcholine and norepinephrine, and Sur and coworkers showed that cholinergic inputs to cortex act via astrocytes to alter the strength of excitatory synapses and implement plasticity of neuronal responses. Furthermore, astrocyte GABA transporters regulate extrasynaptic GABA and influence population coding of visual information by V1 neurons. Astrocyte calcium signaling influences excitatory drive to inhibitory neurons, thereby enabling astrocytes to modulate excitatory-inhibitory balance in neuronal V1 circuits. Astrocytes and learning Glutamate transporters on astrocytes regulate developmental plasticity in visual cortex. Gene expression (of glutamate and GABA transporters) in cortical astrocytes is modulated by learning, and astrocytes thus crucially shape cortical neuronal activity underlying learned behavior.
=== Flexible rechargeable battery electrode === Graphene oxide has been demonstrated as a flexible free-standing battery anode material for room temperature lithium-ion and sodium-ion batteries. It is also being studied as a high surface area conducting agent in lithium-sulfur battery cathodes. The functional groups on graphene oxide can serve as sites for chemical modification and immobilization of active species. This approach allows for the creation of hybrid architectures for electrode materials. Recent examples of this have been implemented in lithium-ion batteries, which are known for being rechargeable at the cost of low capacity limits. Graphene oxide-based composites functionalized with metal oxides and sulfides have been shown in recent research to induce enhanced battery performance. This has similarly been adapted into applications in supercapacitors, since the electronic properties of graphene oxide allow it to bypass some of the more prevalent restrictions of typical transition metal oxide electrodes. Research in this field is developing, with additional exploration into methods involving nitrogen doping and pH adjustment to improve capacitance. Additionally, research into reduced graphene oxide sheets, which display superior electronic properties akin to pure graphene, is currently being explored. Reduced graphene oxide greatly increases the conductivity and efficiency, while sacrificing some flexibility and structural integrity.
=== July === 2 July – Georgie David, the Reform UK candidate for West Ham and Beckton becomes the party's second candidate to suspend their campaign and defect to the Conservatives, and says the "vast majority" of her fellow Reform candidates are "racist, misogynistic and bigoted". The Welsh Government says it plans to bring in a ban on Welsh politicians telling lies before the 2026 Senedd election. 3 July – The Sun endorses the Labour Party ahead of the general election. Essex Police announce that no offences were committed by the Reform UK campaigners recorded making racist comments by Channel 4 News. An investigation concludes that former Conservative government minister Owen Paterson acted as a lobbyist for a healthcare company without being registered to do so. Mick Antoniw, the Counsel General for Wales, apologises after being formally reprimanded by the Senedd for tweeting "Tories so happy to see people and particularly children killed and injured on our roads". A hearing at Newry Magistrates Court rules there is sufficient evidence for former DUP leader Sir Jeffrey Donaldson to stand trial on charges of historical sexual abuse. 4 July – The 2024 United Kingdom general election takes place.
Sources: en.wikipedia.org
It is a synthetic peptide built from 44 amino acids arranged in the same order as human growth hormone-releasing hormone. A short fatty-acid chain, described as a trans-3-hexenoyl group, is attached to the first amino acid. The finished molecule is formulated as a sterile powder that is dissolved before use.
No. It is a releasing-factor analog that signals the pituitary gland to secrete growth hormone, whereas recombinant growth hormone is the hormone itself administered directly. The two are chemically distinct and act at different points in the same endocrine pathway. This distinction is often lost in informal discussion.
Native growth hormone-releasing hormone is broken down within minutes by dipeptidyl peptidase-4 in the bloodstream. Adding the hexenoyl group at the N-terminus shields the peptide from that enzyme. The modification does not change the receptor it targets, only how long the peptide survives in circulation.
It is a synthetic analog of growth hormone-releasing hormone, a hypothalamic peptide. It functions as a growth hormone secretagogue acting at pituitary receptors. The classification separates it from direct growth hormone products.